Results 1 to 10 of about 2,631,955 (205)

Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel. [PDF]

PLoS ONE, 2016
BACKGROUND:Circulating tumor DNA (ctDNA) carries information on tumor burden. However, the mutation spectrum is different among tumors. This study was designed to examine the utility of ctDNA for monitoring tumor burden based on an individual mutation ...
Kei A Sato, Tsuyoshi Hachiya, Takeshi Iwaya, Kohei Kume, Teppei Matsuo, Keisuke Kawasaki, Yukito Abiko, Risaburo Akasaka, Takayuki Matsumoto, Koki Otsuka, Satoshi S Nishizuka   +10 more
doaj   +2 more sources

Beyond tumor mutation burden: tumor neoantigen burden as a superior prognostic biomarker in resected gastric cancer [PDF]

Frontiers in Immunology
IntroductionGastric cancer is one of the most diagnosed cancers and a major contributor to cancer-related death in China. Recent studies have demonstrated the failure of tumor mutational burden (TMB) in predictive accuracy. Here, we aimed to evaluate the
Tingting Lu, Jingyi Cao, Peng Liu, Xiaoxin Pan, Yiming Shen, Jian Wang, Zhida Chen, Yi Liu, Fenglin Zhang, Haiya Zhang, Gan Zhang, Yi Wang, Ji Wan, Hongqing Xi   +13 more
doaj   +2 more sources

High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations

Frontiers in Oncology, 2022
ObjectiveColorectal cancer (CRC) is a common type of malignant tumor of the digestive tract. Tumor mutation burden (TMB) is a potential prognostic indicator of numerous malignant tumors.
Jianlei Wang, Jianping Song, Zeyang Liu, Tingxiao Zhang, Yanfeng Liu   +4 more
doaj   +3 more sources

A case of double‐negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab [PDF]

IJU Case Reports
Introduction Double‐negative prostate cancer, an androgen receptor–independent prostate cancer without features of neuroendocrine tumors, is refractory to treatment but could be an ideal candidate for individualized treatment.
Hiroki Tanaka, Soichiro Yoshida, Satoru Aoyama, Sadakatsu Ikeda, Junko Kunieda, Kenichi Ohashi, Shohei Fukuda, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii   +9 more
doaj   +2 more sources

Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer

Biomedicines, 2021
KRAS mutation is a major regulator in the tumor progression of pancreatic cancer. Here, we compared the frequency and mutation burden of KRAS mutation subtypes with paired tumor tissue and blood in patients and examined their clinical significance.
Eunsung Jun, Bonhan Koo, Eo Jin Kim, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Woohyung Lee, Yejong Park, Sarang Hong, Yong Shin, Song Cheol Kim   +10 more
doaj   +1 more source

LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance

Genes and Diseases, 2023
Accumulating evidence supports the association of somatic mutations with tumor occurrence and development. We aimed to identify somatic mutations with important implications in hepatocellular carcinoma (HCC) and explore their possible mechanisms.
Xiangyu Zhai, Zhijia Xia, Gang Du, Xinlu Zhang, Tong Xia, Delin Ma, Xiaosong Li, Bin Jin, Hao Zhang   +8 more
doaj   +1 more source

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy

Frontiers in Oncology, 2021
Immunotherapy has significantly improved the clinical outcome of patients with cancer. However, the immune response rate varies greatly, possibly due to lack of effective biomarkers that can be used to distinguish responders from non-responders. Recently,
Peipei Wang, Yueyun Chen, Chun Wang
doaj   +1 more source

Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences

Acta Neuropathologica Communications, 2023
Diffuse gliomas are a heterogeneous category of primary central nervous system tumors. Due to their infiltrative growth precluding complete surgical resection, most diffuse high-grade gliomas are treated with adjuvant chemotherapy and radiation ...
Matthew D. Wood, Carol Beadling, Tanaya Neff, Steve Moore, Christina A. Harrington, Lissa Baird, Christopher Corless   +6 more
doaj   +1 more source

Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden

Frontiers in Oncology, 2021
BackgroundTumor mutation burden has been proven to be a good predictor for the efficacy of immunotherapy, especially in patients with hypermutation. However, most research focused on the analysis of hypermutation in individual tumors, and there is a lack
Hong Yuan, Jun Ji, Min Shi, Yan Shi, Jing Liu, Junwei Wu, Chen Yang, Wenqi Xi, Qingyuan Li, Wei Zhu, Jingjie Li, Xiaoli Gong, Jun Zhang, Jun Zhang   +13 more
doaj   +1 more source

Research Progress on Heterogeneity of Tumor Mutation Burden in Patients with 
Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2021
Programmed death ligand 1 (PD-L1) is a well known biomarker for targeted immunotherapy. However, the relationship between the expression of PD-L1 and the immunotherapy efficacy is not always consistent in different cases.
Abdurazik MIHRAY, Peng CHEN
doaj   +1 more source